Opinion

Video

BCMA-Targeted CAR-T Therapies in Development and Future Perspective

Author(s):

Rafat Abonour, MD,Noopur S. Raje, MD

Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.

This is a video synopsis/summary of an OncLive® Post-Conference Perspective involving Rafat Abonour, MD, and Noopur Raje, MD.

Abonour and Raje close by discussing the abundance of B-cell maturation antigen (BCMA)–targeted bispecific T-cell engagers now available for relapsed/refractory multiple myeloma, including the 2 FDA-approved therapies, teclistamab and loncastuximab tesirine, along with linvoseltamab. Response rates are high across the various bispecifics.

The main toxicity requiring vigilant management is immunosuppression with risk for serious infections, even beyond the acute treatment period. Otherwise, bispecifics are very well tolerated, without cytokine release syndrome or neurotoxicity seen after the first couple of cycles.

Raje notes that determining optimal sequencing with other therapies remains an open question. After chimeric antigen receptor T-cell therapy, patients with relapsed disease can typically still benefit from bispecific treatment because BCMA antigen is usually still present. However, the converse may not hold true due to antigen loss after prolonged bispecific exposure.

In conclusion, Abonour and Raje express excitement about the future of BCMA-targeted immunotherapies for patients with multiple myeloma, with questions remaining regarding optimal dosing/scheduling and earlier positioning to further improve durability.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Binod Dhakal, MD
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jill Corre, PharmD, PhD
Related Content
Douglas W. Sborov, MD, MS
October 28th 2024

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Paula Rodriguez-Otero, MD
October 23rd 2024

SC Daratumumab Plus VRd Earns EU Approval in Newly Diagnosed, Transplant-Eligible Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Ashraf Z. Badros, MB, Ch
October 17th 2024

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

Edmond Chan, MBChB, MD, EMEA of Johnson & Johnson
October 10th 2024

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma